Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Pulse Biosciences, Inc.NASDAQ: PLSE

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin at 37.1%

Gross margin was 37.1% in Q2 FY2026. On a trailing-twelve-month basis it was -21.6%. Over 3 fiscal years it widened by 1246.3 pp.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
37.1%+29.4 pp QoQ
Last fiscal yearDec 2025
-360.0%— YoY
LTMJun 2026
-21.6%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years+1246.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-360.0%
Year-over-year change
—

Gross Margin vs competitors

How PLSE compares with its peers on the latest reported figures

  • PLSE's LTM Jun 2026 gross margin of -21.6% is the lowest of the 11 companies compared; the peer median is 81.2%.
  • Over three fiscal years its change of +1246.3 pp compares with a peer median of -2.4 pp.
PLSE Competitors Peer median
Gross Margin for PLSE and competitors
Company Period LTM level YoY 3-year change
IMTXImmatics N.V.LTM Mar 2026100.0% +0.1 pp+61.8 pp
NKTRNektar TherapeuticsLTM Jun 202699.4% +15.9 pp+23.5 pp
DNTHDianthus Therapeutics, Inc.LTM Jun 202696.0% -4.0 pp+0.0 pp
ATAIAtai Beckley Inc.LTM Jun 202686.3% +784.2 pp+47.4 pp
LFMDLifeMD, Inc.LTM Mar 202685.9% -2.1 pp-4.6 pp
STAASTAAR Surgical CompanyLTM Apr 202676.4% +2.4 pp-2.4 pp
NVCRNovoCure LimitedLTM Mar 202675.2% -2.0 pp-4.1 pp
BBNXBeta Bionics, Inc.LTM Mar 202657.2% +3.2 pp-44.6 pp
KMTSKestra Medical Technologies, Ltd.LTM Jan 202648.8% +14.6 pp—
OPKOPKO Health, Inc.LTM Mar 202622.7% -6.2 pp-7.6 pp
PLSEPulse Biosciences, Inc.LTM Jun 2026-21.6% —+1246.3 pp
Peer median (excluding PLSE) 81.2%+1.2 pp-2.4 pp

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.42M700K00350K
Cost of Revenue1.97M11.94M1.21M01.61M
Gross Profit(550K)(11.24M)(1.21M)0(1.26M)
Gross Margin-38.8%-1606.3%——-360.0%
Research & Development28.64M20.84M27.8M32.34M44.72M
Selling, General & Admin33.82M25.97M15.78M23.92M32.03M
Operating Expenses62.46M46.81M42.37M56.26M75.68M
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
EBITDA(62.51M)(57.15M)(39.9M)(52.41M)(71.71M)
EBITDA Margin-4408.6%-8164.3%——-20488.6%
Operating Income(63.01M)(58.06M)(43.57M)(56.26M)(76.94M)
Operating Margin-4443.9%-8293.9%——-21982.6%
Interest Income002.46M2.67M4.21M
Interest Expense646K448K1.1M00
Other Income / Expenses(646K)(448K)1.36M2.67M4.16M
Income Before Tax(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Pre-Tax Margin-4489.4%-8357.9%——-20794.6%
Income Tax Expense00000
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Net Margin-4489.4%-8357.9%——-20794.6%
EPS (Basic)(2.28)(1.72)(0.88)(0.92)(1.08)
EPS (Diluted)(2.28)(1.72)(0.88)(0.92)(1.08)
Weighted Avg Shares27.96M33.94M48.04M58.4M67.4M
Weighted Avg Shares (Diluted)27.96M33.94M48.04M58.4M67.4M

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.